Posted by Michael Wonder on 03 Apr 2018
Atopic dermatitis patients to be denied NHS access to Dupixent
3 April 2018 - NICE has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
The draft guidelines highlight that Dupixent (dupilumab) is effective at treating moderate-to-severe atopic dermatitis following failure (or contraindication) of topical therapies and systemic immunosuppressant agents.
However, the Institute said cost-effectiveness estimates for the drug were uncertain, and higher than that normally considered an acceptable use of NHS resources.
